AN2 Therapeutics reported topline results from the Phase 2/3 EBO-301 study of epetraborole in treatment-refractory MAC lung disease. The study showed similar sputum culture conversion rates between treatment arms, leading to the trial's termination and a 50% workforce reduction.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow traded up 0.52% to 38,873.28 while the NASDAQ fell 0.10% to 15,975.16. The S&P 500 also rose, gaining, 0.12% to 5,032.46.
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1.
